18
Dr.WAN NEDRA Sp.A Child Health Dept. School of Medicine University of YARSI

Anak Hepatitis

Embed Size (px)

Citation preview

Page 1: Anak Hepatitis

Dr.WAN NEDRA Sp.AChild Health Dept.School of MedicineUniversity of YARSI

Page 2: Anak Hepatitis

• organ paling besar

• Fungsi utama:1. Regulasi Metabolite dalam dara2.Detoxikasi

• RegenerateRegenerate jk terjadi jk terjadi kerusakankerusakan

Old Old ErythrocytesErythrocytesSpleen

Urobi-Urobi-linogelinogenn

Small amount –entero-hepatic circulation

StercobiliStercobilinene

HEPATITISHEPATITIS• Inflammasi & Inflammasi & necrosisnecrosis• Infeksi & non InfInfeksi & non Inf

Conj. Conj. bilirubibilirubinn

Unconj Unconj bilirubinbilirubin

Page 3: Anak Hepatitis

Morbidity - mortality Epidemiology – endemic area

carrier rate - transmission rate Therapeutics ? Quality of life?

Prevention - !!!

Page 4: Anak Hepatitis

Epidemiology, virology, patophysiology: Diagnosis DINI Supportive & monitoring Detection dini:

fulminant, chronicity Prevention of spreading Pengobatan Antivirus

Page 5: Anak Hepatitis

HAVHAV HBVHBV HCVHCV HGVHGVVirusVirus PicornaPicorna HepadnHepadn

aaFlaviFlavi FlaviFlavi

InkubasiInkubasi 15-40 hr15-40 hr 50-50-160hr160hr

1-5 bln1-5 bln ? 2 mg? 2 mg

OnsetOnset AkutAkut SubklinikSubklinik SubkliniSubklinikk

Akut/subAkut/sub

Oral-fekalOral-fekalParenteraParenterall

(++)(++)JarangJarang

(-)(-)(++)(++)

(-)(-)(++)(++)

(-)(-)(++)(++)

KronisitaKronisitass

(-)(-) (+)(+) (+)(+) (+)(+)

Page 6: Anak Hepatitis
Page 7: Anak Hepatitis

Endemic - young children – reservoir Morbidity – mortality at older age

Complication in chronic liver Complication in chronic liver disease – 8xdisease – 8xSelf Self

limiting limiting diseasedisease

Single Single exposurexposuree

Long Long life life immuniimmunityty

Page 8: Anak Hepatitis

HAV PathogenesisHAV Pathogenesis

CTL HepatocyteReceptor

Excretion in stool Excretion in bile

Page 9: Anak Hepatitis

OUTCOMEOUTCOMEHAV infectionHAV infection

DeathDeath

Asymptomatic

Non icteric

IctericIcteric

Complication -

Relapsing

Cholestatic

Liver Liver failurefailure

ResolvedResolved

TransplantatioTransplantationn

HAV infectionHAV infection

Page 10: Anak Hepatitis

Anti HAV total

IgM-Anti HVAIgM-Anti HVAHVAstool

Page 11: Anak Hepatitis

Heat stable virus Endemic - reservoir Fecal-oral, kontak erat High risk: children, CLD cases, etc

Susceptible: High sosio-economic population  

Page 12: Anak Hepatitis

Hygiene - sanitation Proper cooking, hand washing, septic

tank,diapers, etc Isolate index case

Immunization Pre-post exposure (active–passive)

Page 13: Anak Hepatitis

IgM anti HAV (+)IgM anti HAV (+)

PT/INRPT/INR

INR < 2INR < 2

RepeatRepeat LFTs 5–7 LFTs 5–7 dd

ImprovedImproved

Repeat LFT 6wk

Normal – No follow up

AbnormalAbnormal

Not improvedNot improved(clinic-

laboratory)

INR > 2INR > 2 ReferRefer

Page 14: Anak Hepatitis

Long immunity Simultaneous -

other vaccine Interchangeable Serologic test:

pre- likely exposed post- vaccination: (-)

Individual risk: Children, CLD cases, IVDU, homosexuals multitransfused, household contact, traveler - low endemic

Professional risk: food sector, health, sewage, waste water, in contact with children, lab-military staff

PENCEGAHAN PENCEGAHAN VAKSIN VAKSIN HVA HVA

Inactivated, safeInactivated, safe

Page 15: Anak Hepatitis

AgeAgeysys

Routine Routine immunization immunization

Individual Individual Community Community protectionprotection

Post-Post-exposureexposure

immunizationimmunization< 2< 2 Vaccine (-)Vaccine (-) NHIGNHIG –– household household

contactcontact2 – 2 – 1818

HavrixHavrix 720 EU, 720 EU, AvaximAvaxim 160 AU/ml, 2x (0, 6 – 12)160 AU/ml, 2x (0, 6 – 12)

VaccineVaccine or or Vaccine & NHIG#Vaccine & NHIG#

> 18> 18 HavrixHavrix 1440 EU, 1440 EU, AvaximAvaxim 160 AU/ml, 2x (0, 6 – 12)160 AU/ml, 2x (0, 6 – 12)

None None or or VaccineVaccine or or Vaccine & NHIG#Vaccine & NHIG#

Protective – anti HAV Protective – anti HAV 20 mIU/ml 20 mIU/ml

Page 16: Anak Hepatitis

AGEAGE(ys)(ys)

DURATION DURATION protectionprotection

RECOMMENDATIONRECOMMENDATION

< 2< 2 < 3 months< 3 months3-5 months3-5 monthsLong termLong term

NHIG 0.02 ml/kg, 1xNHIG 0.02 ml/kg, 1xNHIG 0.02 ml/kg, 1xNHIG 0.02 ml/kg, 1xNHIG 0.06 ml/kg, repeat NHIG 0.06 ml/kg, repeat 5/125/12

2 2 < 3 months< 3 months3-5 months3-5 monthsLong termLong term

Vaccine or NHIG (0.02 Vaccine or NHIG (0.02 ml/kg)ml/kg)Vaccine or NHIG (0.06 Vaccine or NHIG (0.06 ml/kg)ml/kg)VaccineVaccine

Page 17: Anak Hepatitis

ReferRefer

ReferRefer

IgM HAVIgM HAV(+)(+)

IgM HAV (–)

Treat as HAV

ReferReferBilirubin Bilirubin > 6 mg/dl> 6 mg/dl

GGT – cholestatic or GGT – cholestatic or obstructionobstruction

Bilirubin Bilirubin > 6 mg/dl> 6 mg/dl

Alanine transaminaseAlanine transaminase

Initial consultationInitial consultation: - LFTs- LFTs - Anti HAV-IgM- Anti HAV-IgM - HBsAg- HBsAg

Page 18: Anak Hepatitis